Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent

European Heart Journal

Volumn 25, Issue 15, 2004, Pages 1330-1340

  Vogt, Felix ^a   Stein, Andreas ^a   Rettemeier, Gösta ^b   Krott, Nicole ^a   Hoffmann, Rainer ^a   Dahl, Jürgen Vom ^a   Bosserhoff, Anja Katrin ^c   Michaeli, Walter ^b   Hanrath, Peter ^a   Weber, Christian ^a   Blindt, Rüdiger ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Paclitaxel; Polymer; Restenosis; Stents

Indexed keywords

LACTIC ACID DERIVATIVE; PACLITAXEL; POLYLACTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON CATHETER; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEASIBILITY STUDY; HISTOPATHOLOGY; IMPLANTATION; INFLAMMATION; LONG TERM CARE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SWINE;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; DRUG IMPLANTS; FEASIBILITY STUDIES; MODELS, ANIMAL; PACLITAXEL; POLYESTERS; RANDOM ALLOCATION; STENTS; SWINE; TUNICA INTIMA;

EID: 3242877692     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.06.010     Document Type: Article

References (33)

1. Hoffmann R., Mintz G.S. Coronary in-stent restenosis - predictors, treatment and prevention. Eur. Heart J. 21:2000;1739-1749
2. Leon M.B., Teirstein P.S., Moses J.W., et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N. Engl. J. Med. 344:2001;250-256
3. Tamai H., Igaki K., Kyo E., et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation. 102:2000;399-404
4. Yamawaki T., Shimokawa H., Kozai T., et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol. 32:1998;780-786
5. Ye Y.W., Landau C., Willard J.E., et al. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann. Biomed. Eng. 26:1998;398-408
6. van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94:1996;1690-1697
7. Agrawal C.M., Haas K.F., Leopold D.A., et al. Evaluation of poly (L-lactic acid) as a material for intravascular polymeric stents. Biomaterials. 13:1992;176-182
8. Badimon L., Meyer B.J., Badimon J.J. Thrombin in arterial thrombosis. Haemostasis. 24:1994;69-80
9. Hall J.D., Rittgers S.E., Schmidt S.P. Effect of controlled local acetylsalicylic acid release on in vitro platelet adhesion to vascular grafts. J. Biomater. Appl. 8:1994;361-384
10. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138:1999;S419-S420
11. Honda Y., Grube E., de La Fuente L.M., et al. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation. 104:2001;380-383
12. Liistro F., Stankovic G., Di Mario C., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long- term clinical and angiographic outcome. Circulation. 105:2002;1883-1886
13. Degertekin M., Serruys P.W., Foley D.P., et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 106:2002;1610-1613
14. Regar E., Serruys P.W., Bode C., et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 106:2002;1949-1956
15. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:2003;1315-1323
16. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:2003;38-42
17. Tanabe K., Serruys P.W., Degertekin M., et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation. 109:2004;196-200
18. Tanabe K., Serruys P.W., Grube E., et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 107:2003;559-564
19. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350:2004;221-231
20. Blindt R., Hoffmeister K.M., Bienert H., et al. Development of a new biodegradable intravascular polymer stent with simultaneous incorporation of bioactive substances. Int. J. Artif. Organs. 22:1999;843-853
21. Rogers C., Tseng D.Y., Squire J.C., et al. Balloon-artery interactions during stent placement: a finite element analysis approach to pressure, compliance, and stent design as contributors to vascular injury. Circ. Res. 84:1999;378-383
22. von Oepen R. Development of specific engineering and fabrication techniques for the production of degradable implants. Institute of Plastic Processing, RWTH Aachen University, 52074 Aachen, Germany, 1996
23. Schwartz R.S., Huber K.C., Murphy J.G., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 19:1992;267-274
24. Blindt R., Zeiffer U., Krott N., et al. Upregulation of the cytoskeletal-associated protein Moesin in the neointima of coronary arteries after balloon angioplasty: a new marker of smooth muscle cell migration. Cardiovasc. Res. 54:2002;630-639
25. Asai J. Methods in cell biology. Antibodies in Cell Biology. 37:1993;Academic Press, San Diego, CA
26. Peng T., Gibula P., Yao K.D., et al. Role of polymers in improving the results of stenting in coronary arteries. Biomaterials. 17:1996;685-694
27. Hietala E.M., Salminen U.S., Stahls A., et al. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J. Vasc. Res. 38:2001;361-369
28. Lincoff A.M., Furst J.G., Ellis S.G., et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J. Am. Coll. Cardiol. 29:1997;808-816
29. Axel D.I., Kunert W., Goggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 96:1997;636-645
30. Heldman A.W., Cheng L., Jenkins G.M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 103:2001;2289-2295
31. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 106:2002;2649-2651
32. Grube E., Gerckens U., Muller R., et al. Drug eluting stents: initial experiences. Z. Kardiol. 91(Suppl 3):2002;44-48
33. Virmani R., Kolodgie F.D., Farb A., et al. Drug eluting stents: are human and animal studies comparable. Heart. 89:2003;133-138